Search Results - thomas+dexheimer

2 Results Sort By:
Inhibition of Thioredoxin Reductase 1 (Trxr1) by Pyridine Compounds for Cancer Treatment
This technology includes the use of pyridines for anticancer treatment. A common feature of cancer cells is a high level of reactive oxygen species with a concomitant increase of two antioxidative systems to combat the toxicity: the glutathione and thioredoxin systems. Inhibiting either, or both, of these systems is a promising avenue to target cancer...
Published: 10/28/2024   |   Inventor(s): Ajit Jadhav, Diane Luci, Thomas Dexheimer, Anton Simeonov, Nathan Coussens, David Maloney
Keywords(s): CANCER, Novel, PYRIDINES, Their, treatment, VCXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): Application > Research Materials, TherapeuticArea > Oncology, Application > Therapeutics
Highly Potent and Selective Deubiquitinating Enzyme Inhibitor
Available for licensing are inhibitors that target the USP1/ UAF1 deubiquitinating enzyme (DUB) complex. The FDA approval and commercial success of Velcade®, a small molecule proteasome inhibitor, has established the ubiquitin-proteasome system (UPS) as a valid target for anticancer treatment. However, proteasome inhibitors in general suffer from...
Published: 10/28/2024   |   Inventor(s): Andrew Rosenthal, Ajit Jadhav, Thomas Dexheimer, Anton Simeonov, Qin Liang, Zhihao Zhuang, David Maloney
Keywords(s): CANCER, CANCER THERAPEUTICS, CB5XXX, CB7XXX, CBXXXX, Combination Therapy, CXXXXX, Deubiquitinase, Inhibitors, POTENT, protease inhibitors, SELECTIVE, small molecule, USP1/UAF1
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics